Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

GSK Awarded $41M DoD Contract to Further Antibacterial Research

  • GlaxoSmithKline inked a $41 million agreement from the Defense Threat Reduction Agency of the DoD. The funding, which will be provided over five years, will be used to identify and develop a class of antibacterials targeting gram-negative biothreats and conventional hospital pathogens.

    GSK says that it will also contribute to this effort by providing supplemental staff and covering other program costs. The research will focus on gram-negative pathogens such as Pseudomonas, Klebsiella, and Acinetobacter, which are increasingly resistant to all known classes of antibiotics.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »